The Best-Performing ETF Has a Winning Strategy, But Just $29 Million
- A Virtus biotech fund posted the biggest return last month
- Trial results and M&A has spurred confidence in the sector
Photographer: Tomohiro Ohsumi/Bloomberg
This article is for subscribers only.
Size doesn’t matter for one exchange-traded fund that’s beating the competition.
A fund with just $29 million was the star performer in the $4 trillion U.S. market last month, returning more than any other unleveraged ETF, data compiled by Bloomberg show. The Virtus LifeSci Biotech Clinical Trials fund, which trades under the ticker BBC, gained 22%, beating more than 1,970 rivals.